 |
Known
in the industry as the “Alpha Scientist,”
Dr. Allen is in the forefront of scientific breakthroughs,
including Nanotechnology, NanoMolecules, Quantum Chocolate,
Genetic polymorphisms in Dysregulated Arginine Metabolism,
Sickle Cell Polymorphisms, Thalassemia, Blind Amino
Acid Riders, L-Arginine Isoform Pathways, and Edible
Computer Chips.
|
|
|
PATENTS
Dr.
Allen received the first patent granted worldwide on the
Glycemic Index, and conducts Human Glycemic In Vivo Clinical
Trials for the food, Nutraceutical, and Pharmaceutical industry.
Dr.
Allen's Patents span over two decades, and have been featured
on the front page of the Wall Street Journal, and named
"Breakthrough Product of the Year" by Success
magazine. (click for patents section).
FUTURE-SCIENCE The
medical and research community states that Dr. Allen's science
and technology is "Twenty years ahead of everyone else."
Known
in the industry for her bold stance of setting high standards
in scientific accuracy, Dr. Allen went so far as to correct
Discover magazine, whose educational publication is considered
the gold standard in science. Her statement on quaternary
saturated amines prompted a correction by Discover.
For
over twenty years, Dr. Allen had warned of the dangers of
using L-arginine without a Blind Amino Acid Rider. Her stance
on L-arginine was validated in January 2006, when the Journal
of the American Medical Association (JAMA) published the Johns
Hopkins clinical trial on oral L-arginine, in which L-arginine
was shown to cause death in a significant segment of the subjects,
which prompted the close of the clinical trial. (www.ArginineAnswers.com)
As
a result of her long-term research on the amino acid L-arginine,
the medical and scientific community refered to Dr. Allen
as the Leader in L-Arginine Biochemistry, and the Queen of
Arginine.
When
Dr. Allen was asked by the media how she is able to stay on
the leading edge of future-science, she replied:
“Part
science, part skill, and part intuition. I also credit my
savant-dyslexia. A dyslexic’s nonlinear images allows
them to think much more quickly and multi-dimensionally. Albert
Einstein was savant-dyslexic. Einstein was able to develop
his theory of relativity due to his dyslexic properties of
creativity and ability to make intuitive leaps. Intuitive
leaps allow me to ignore conventional science and make theoretical
bonds with nutritional concepts. The key then, is to scientifically
prove these concepts.”
As
a tribute to Einstein, in 1983 Dr. Allen named her L-Arginine
Isoform Pathway L-Arginine M².
|
|
 |
|
Dr.
Ann de Wees Allen
Chief Researcher
Skinny Science ® Biomedical Team
Human In Vivo Clinical Research
www.SkinnyScience.com
www.SkinnyScienceEdu.com
Dr. Allen's Skinny Science ® research team has discovered
the KEY CODE for fat-storage in
the fat cell, identifying which foods store in human fat cells
and which foods do not store in fat cells, and why diet sodas
are more fattening than a bowl of sugar. |
 |
Skinny
Science ® is a branch of biomedical research that
refers to weight management in humans, adipose tissue
fat-storage, fat-storing mechanisms, Cephalic effect,
thermogenic fat-burning, and Low Glycemic methodologies. |
|
|
|
|
ENCODE®
RESEARCH TEAM
www.EncodeResearch.com
The
ENCODE® Research Team includes Dr. Ann de Wees Allen &
Dr. Clair Francomano.
Clair
Francomano, M.D.
Chief,
Human Genetics, Gene Foundation
BA,
Yale University, Magna Cum Laude
M.D.,
Johns Hopkins University School of Medicine
Medical
Board, Johns Hopkins Hospital
Chief,
Medical Genetics Branch, National Institutes of Medicine
(NIH),
National Genome Research Institute (1994-1999)
Chief,
Human Genetics, National Institute of Aging (NIA) (2001-2005)
Dr.
Clair Francomano is named as one of the top genetic
researchers in the world. |
|
|
Copyright © 2007-2009 DrAllenResearch.com
|
